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  PRotoCoL
A multicentre prospective randomized 
equivalence trial of a soft bandage and 
immediate discharge versus current 
treatment with rigid immobilization 
for torus fractures of the distal radius 
in children
PROtOCOl fOR the fOReaRm fRaCtuRe ReCOveRy in ChilDRen 
evaluatiOn (fORCe) tRial
Aims
Torus fractures are the most common childhood fracture, accounting for 500,000 UK emer-
gency attendances per year. UK treatment varies widely due to lack of scientific evidence. 
This is the protocol for a randomized controlled equivalence trial of ‘the offer of a soft band-
age and immediate discharge’ versus ‘rigid immobilization and follow- up as per the proto-
col of the treating centre’ in the treatment of torus fractures .
Methods
Children aged four to 15- years- old inclusive who have sustained a torus/buckle fracture of 
the distal radius with/without an injury to the ulna are eligible to take part. Baseline pain 
as measured by the Wong Baker FACES pain scale, function using the Patient- Reported Out-
comes Measurement Information System (PROMIS) upper limb, and quality of life (QoL) as-
sessed with the EuroQol EQ- 5D- Y will be collected. Each patient will be randomly allocated 
(1:1, stratified by centre and age group (four to seven years and ≥ eight years) to either a 
regimen of the offer of a soft bandage and immediate discharge or rigid immobilization and 
follow- up as per the protocol of the treating centre.
Results
At day one, three, and seven, data on pain, function, QoL, immobilization, and analgesia 
will be collected. Three and six weeks after injury, the main outcomes plus data on complica-
tions, resource use, and school absence will be collected. The primary outcome is the Wong- 
Baker FACES pain scale at three days post- randomization. All data will be obtained through 
electronic questionnaires completed by the participants and/or parents/guardian.
Cite this article: Bone Joint Open 2020;1-6:214–221.
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Strength and limitations
 Broad eligibility criteria to ensure 
generalizability.
  Patient- centred outcome data.
  assessment of outcomes at multiple 
time points will allow for information on 
recovery profile.
  in addition to a comparison of clinical 
outcomes, a health economic evaluation 
will be performed.
 it will not be possible to blind patients and 
care givers to their allocated treatment.
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Introduction
torus (buckle) fractures of the distal radius are the most 
common fractures in children, with the bone ‘buckling’, 
so there is deformation without a break in the cortex. 
they result from trauma to growing bones and account 
for 500,000 uK emergency attendances annually.1
they are very low risk injuries for complications or 
deformity in the skeletally immature, and these fractures 
universally heal well.2
there is considerable variation in the management of 
torus fractures. treatment varies from the use of a remov-
able rigid splint, to plaster cast immobilization, to more 
flexible splints. the variation in practice has arisen from a 
longstanding taught doctrine of rigid immobilization for 
fractures,3 tempered with newer evidence to suggest that 
simpler treatment methods are frequently as effective or 
perhaps even more effective.4-8 the proponents of rigid 
forms of immobilization (i.e. cast/splint) argue that this 
maximizes pain relief, and minimises the occurrence of 
complications, i.e. refracture. however, there is growing 
evidence to support the absence of complications with 
growing acceptance that rigid immobilization may not 
improve pain control but will unduly restrict function, 
and that patients may safely be discharged at diagnosis.7,9 
two systematic reviews support the abandonment of 
non- removable rigid casts in favour of splints removable 
at home.10,11
the recent niCe non- complex fracture guidelines 
made recommendations on the management of these 
injuries.1 the interventions considered as part of this 
review were non- removable rigid casts (i.e. fibre-
glass/plaster of Paris), soft casts, removable splints 
and bandaging. the niCe review group concluded 
that bandaging was probably the optimal treatment 
approach, due to the convenience, adequate pain 
control and the ability to promote early function. the 
niCe review concluded that torus fractures of the distal 
radius should not be immobilized in a non- removable 
rigid cast, and advocated discharge from the emergency 
department without a subsequent need for outpatient 
follow- up. niCe questioned whether any intervention 
was necessary at all, and subsequently recommended a 
trial to determine the optimal intervention. to summa-
rize, there are several options for the treatment of 
torus fractures of the distal radius, with key differences 
relating to the degree of immobilization provided, 
and the follow- up required. Soft bandaging restricts 
movement the least and may promote early function, 
but concern remains about pain and the potential for 
complications, despite evidence to the contrary. this is 
the protocol of a randomized equivalence trial of soft 
bandage with immediate discharge versus immobiliza-
tion with a splint as per current practice.
the trial will be reported in line with the 
COnSORt statement using the non- pharmacological 
treatment interventions and patient reported outcomes 
extensions.12,13
Aims
the aim of this project is to establish whether treating 
children with a torus fracture of the distal radius with 
the offer of a soft bandage and immediate discharge 
provides the same recovery, in terms of pain and func-
tion, as treating them with rigid splint immobilization 
and follow- up as per the protocol of the treating centre.
the primary objective is:
to quantify and draw inferences on observed differ-
ences in the Wong- Baker faCeS Pain Rating Scale 
(Wong- Baker scale) between soft bandage and imme-
diate discharge versus rigid immobilization and standard 
follow- up, at three days post- randomization.
the secondary objectives are:
1. to assess differences in the Wong- Baker scale between 
trial treatment groups at one day, seven days, three 
weeks, and six weeks post randomization
2. to determine differences in the use of regular anal-
gesia between trial treatment groups at one day, three 
days, and seven days post- randomization.
3. to quantify and draw inferences on functional 
recovery using the PROmiS upper limb limb Score for 
Children Computer adaptive test (a validated measure of 
childhood upper limb function) between the trial treat-
ment groups at three days, seven days, three weeks, and 
six- weeks post- randomization
4. to quantify and draw inferences on observed differ-
ences in the eQ- 5Dy (a validated assessment of health- 
related quality of life) between trial treatment groups 
at three days, seven days, three weeks, and six- weeks 
post- randomization.
5. to determine differences in the number of days of school 
absence between trial treatment groups up to six- weeks 
post- randomization.
6. to determine differences in the complication rate 
between trial treatment groups, including the need 
for further hospital attendance up to six- weeks 
post- randomization.
7. to investigate, using appropriate statistical and econom-
ic analysis methods, the resource use, and comparative 
cost- effectiveness between trial treatment groups 
during the first six weeks after injury.
outcome measures. a schedule of data collection is out-
lined in table i.
to determine the most appropriate primary outcome 
we discussed the proposed trial with children and fami-
lies affected by torus fractures of the distal radii, and 
consulted fifteen members of the GenerationR nihR 
young person's advisory group (yPaG). Children indi-
cated that pain was the most important outcome, 
particularly in the first few days after the injury, with 
early function as a secondary concern. Parents were 
similarly concerned by pain, function and in addition 
the duration of school absence. With input from these 
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table I. Outcomes collection schedule.
Baseline
Wong- Baker FACES 
Pain Scale,
PRoMIS upper limb 
(UE) for Children
EQ- 5D- Y
Prior to 
randomization in 
the emergency 
department.
Day 1 Wong- Baker faCeS Pain 
Scale,
use of immobilization 
(y/n),
analgesia y/n
treatment satisfaction
electronic collection
Day 3 Wong- Baker faCeS 
Pain scale (primary 
outcome),
PROmiS- ue,
eQ- 5D- y,
use of immobilization 
(y/n),
use of analgesia (y/n).
electronic collection
Day 7 Wong- Baker faCeS Pain 
scale,
PROmiS- ue,
eQ- 5D- y,
use of immobilization 
(y/n),
use of analgesia (y/n).
electronic collection
3 weeks Wong- Baker faCeS Pain 
scale,
use of immobilization 
(y/n),
Days of school absence,
PROmiS ue,
eQ5D- y
economics questionnaire.
electronic collection
6 weeks Wong- Baker faCeS Pain 
scale,
Days of school absence,
PROmiS ue,
eQ5Dy
economics questionnaire
treatment satisfaction
electronic collection
groups we resolved to measure pain at three days post- 
randomization as the primary outcome. We presented 
children of the yPaG several valid pain scores used in 
children (‘faces Pain Scale- Revised’, ‘Wong- Baker scale’ 
and ‘Oucher’). Children indicated a preference for the 
use of the Wong- Baker scale. We then tested the use 
of this measure, and it’s electronic collection in a small 
feasibility study.14 this study confirmed that early pain 
was of primary significance related to this injury, with 
pain almost resolved at three weeks.
the primary outcome measure for this study is there-
fore the Wong- Baker scale at three days.15 this is a vali-
dated self- reported tool. it is an ordinal assessment of 
pain using a series of six facial- expressions to illustrate the 
degree of pain intensity. a numerical rating is assigned 
to each face (from 0, “no hurt” to 10, “hurts worst”). 
it has been validated for use among children over 
three- years- old, including in the paediatric emergency 
department16; with its use being most established from 
five- years- old.4,17 it has been identified to be an excellent 
measure of pain when estimating the effect of treat-
ment interventions in the emergency department, and 
is highly correlated to the visual analogue scale (r = 0.90 
p < 0.001).16 test- retest reliability is excellent, r = 0.90, p 
< 0.001.18 the Wong- Baker scale is widely used in clinical 
practice, forming part of the Royal College of emergency 
medicine ‘Composite tool for the assessment of pain 
in children’ produced in 2013 as part of a best practice 
guideline,1 and was recently specifically highlighted for 
use by the niCe major trauma guidelines.19
the secondary outcome measures are:
Functional Recovery - Patient Report outcomes 
Measurement System (PRoMIS Bank v2.0)
Upper Limb Score for Children Computer Adap-
tive test (CAt)
PROmiS is a collection of patient- reported health 
status tools available for children and adults that were 
developed to be disease nonspecific in collaboration with 
the uS national institute for health.20,21 these tools can 
be administered to healthy children as well as to children 
with a variety of chronic health conditions. they are self- 
reported from eight- years- old, and proxy- reported below 
eight- years- old. PROmiS is available in full (30 questions), 
short- form (eight questions) or as a computer adaptive 
test “Cat” (average eight questions). a Cat enables the 
answer from one question to inform the choice of the 
next question; so each child completing a Cat could 
answer a distinct set of questions to arrive at their score.
Analgesia use. it is established that the analgesia used 
in the management of torus fractures are simple over- 
the- counter medications; paracetamol and ibuprofen. 
Patients are typically asked to purchase these over- the- 
counter, or out of daytime hours may be given a short 
supply. information concerning the use of analgesia will 
be sought at a binary level to their use in the last 24 hours.
Quality of life (EQ-5D-Y). this is the child- friendly version 
of the eQ- 5D- 3l, which has been especially adapted in 
terms of language for children aged eight to 11 years and 
for adolescents aged 12 to 18 years.22,23 a proxy version is 
available for younger children. its age appropriateness in 
terms of feasibility, reliability and validity in children and 
adolescents has been established.24
Days of absence from school/childcare. School absence due 
to injury will be recorded as well as days of purchased 
childcare and lost working days due to child’s injury.
Complications. all complications will be recorded. 
Particular note will be made of hospital re- attendance re-
lated to the index injury including inadequate analgesia, 
refracture or worsening of the fracture.
Healthcare utilization. this will be monitored for the eco-
nomic analysis. unit cost data will be obtained from na-
tional databases such as the Bnf, nhS Reference Costs, 
and PSSRu Costs of health and Social Care. Where these 
are not available the unit cost will be estimated in con-
sultation with the Oxford university hospitals finance 
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department. nhS costs and participants’/parents’ out- 
of- pocket expenses will be recorded via a short question-
naire which will be administered at three and six weeks 
post- randomization.
throughout the internal pilot phase, completion 
rates of outcome measures will be carefully monitored. 
a review of these rates will be discussed by the trial 
management group on a monthly basis, with potential 
interventions, such as paper CRfs or reminder phone 
calls, discussed and implemented prior to the start of the 
main RCt recruitment phase.
Sample size
Wong-Baker FACES scale. the primary outcome is the 
six- category Wong- Baker scale at three days.17 the 
Wong- Baker scale has a minimally clinical important 
difference (mCiD) of one face, which was determined 
in the setting of the paediatric emergency depart-
ment.16 the Wong- Baker scale demonstrates a very 
high correlation with the vaS, with each face corre-
sponded to approximately 17 mm on the vaS and a 
clinically important difference in pain.16 each face 
equates to two points on the six- category Wong- Baker 
scale. this trial will demonstrate equivalence of a soft- 
bandage to rigid immobilization assessing the differ-
ence in means on the Wong- Baker scale at three days 
post- randomization. assuming an equivalence margin 
of one point (half the mCiD), 90% power, one- sided 
2.5% significance, and assuming that the standard de-
viation (SD) is 2.3 (based on results from a feasibility 
study), 278 patients (139 per arm) would be required 
to show equivalence.
Consideration must also be made of the fact that Wong- 
Baker scale is a categorical outcome that may behave 
non- linearly in some instances (i.e. the magnitude of pain 
within the intervals is not uniform), with non- linearity 
more likely in younger age- groups, tending to linearity in 
those over eight years old.25 We therefore have powered 
the trial for equivalence separately in the two subpopula-
tions (< eight years of age and ≥ eight years age), which 
is also important for secondary outcomes where some 
are proxy- reported for participants less than eight years 
and patient- reported for eight years and above. there-
fore, the trial is powered separately for equivalence in the 
two sub- populations (four to seven- year- olds and eight 
to 15- year- olds). in all, 278 participants with primary 
outcome data in each group will be required to show 
equivalence.
allowing for 20% loss to follow- up inflates the sample 
size to 348 in each of the sub- populations (174 per 
arm). Given the primary outcome is at three days post- 
randomization, the loss to follow- up inflation can be 
readily adjusted to ensure the study recruits effectively 
and efficiently. Sample size calculations were performed 
in PaSS (PaSS 13 Power analysis and Sample Size Soft-
ware (2014). nCSS, Kaysville, utah, uSa).
Methodology
Children will be eligible for inclusion into the trial if:
 there is radiological evidence of a torus fracture of the 
distal radius whereby there is a cortical deformation 
within the distal third of the radius but no break in 
the cortex. these may be associated with an ipsilateral 
fracture to the ulna* (the ulna fracture may be buckle, 
greenstick or otherwise).
  they are aged four- to 15- years- old inclusive.
 Randomization must occur at the site able to defin-
itively treat the injury (i.e. a centre able to take the 
decision regarding the definitive treatment approach, 
which will typically be the emergency department).
* Give the anatomy of the area, most children will have an 
injury to both the radius and the ulna bones but, through 
randomization, patients with a concomitant ulna fracture 
will be balanced between the intervention groups.
Children will be excluded from this trial if:
 the injury is more than 36 hours old.
  the treating clinician judges that there is a cortical 
disruption of the radius on radiographs (i.e. a green-
stick fracture).
  they have sustained an additional fracture at the time 
of the index fracture (with the exception of ipsilateral 
ulna fractures). any child with bilateral torus fractures 
will therefore be excluded.
 there is evidence that the patient and/or parent/
guardian would be unable to adhere to trial proce-
dures or complete follow- up, such as insufficient 
english language comprehension, developmental 
delay or a developmental abnormality or no access 
by parents/guardians to a mobile telephone with 
internet access.
Consenting. Recruitment will take place in a minimum 
of 15 nhS trusts who treat children with torus fractures 
of the distal radius in the uK. eligible patients will be 
identified by the clinical team. the research associate 
will present the patient and parents/guardian with age- 
appropriate participant information sheets or online 
study information and verbal explanation of the trial pro-
cedures. the patient/parent/guardian will then be given 
the opportunity to discuss any issues related to the trial 
with the research associate and members of their family 
and friends. the parent/guardian will then be asked to 
sign an electronic informed consent form, and children 
from eight years will be invited to sign an electronic as-
sent form. assent should be taken where appropriate, 
however the absence of assent does not exclude the pa-
tient from the study if consent has been obtained from 
the parent/guardian. if a child indicates dissent or indi-
cates they do not what to take part, the child will not be 
included in the study.
Randomization. those patients who consent to take 
part in the trial will have their treatment allocated us-
ing a secure, centralised, online randomization service. 
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all hospital treatment areas have access to the internet 
so will access the randomization service in real time i.e. 
there will be no delay in patient treatment.
Consented participants will be randomized to one of 
two intervention groups (1:1) using a computer random-
ization service provided by the Oxford Clinical trials 
Research unit (OCtRu). Randomization allocation will be 
implemented using stratification by centre and age (four 
to seven years, ≥ eight years) with randomization sched-
ules prepared by the trial statistician and embedded in 
the online system.
Stratification by centre will help to ensure that 
any clustering effect related to the centre will be equally 
distributed in the trial arms. the catchment area (the 
local population served by the hospital) will be similar 
for all of the hospitals; each hospital being a children’s 
injury unit dealing with these fractures on a daily basis. 
all of the recruiting hospitals, and indeed all hospitals 
throughout the nhS, use these techniques as part of their 
normal practice i.e. staff will already be equally familiar 
with both forms of treatment. this cannot eliminate 
the clinician- specific effect of an individual at any one 
centre.26 however, since the procedures are common-
place across the nhS, many clinicians will be involved 
in the management of this group of patients; likely 
between 20 and 50 clinicians at each centre, including 
consultants, trainees and specialist nurses. therefore, we 
anticipate that each individual clinician will only treat a 
handful of those enrolled in the trial, reducing the risk of 
a clinician- specific effect upon the outcome in any one 
centre.
Stratification on the basis of age will ensure 
that the treatments are balanced across the age groups. 
this will take into account differences in the properties 
of the primary outcome by age, with the score tending 
to linearity in those around eight years onwards, but 
behaving non- linearly for those under eight years.25 
furthermore, there is a discontinuity within the secondary 
outcome instruments, i.e. self- reports for those ≥ eight 
years old, and proxy- reports for those < eight years old 
for secondary outcomes. the trial therefore considers 
children < eight years, separately to those ≥ eight years to 
ensure the maximum validity of the result generated, and 
to maximize the generalizability of the trial results.
Post-randomization withdrawals. Participants (or their 
parents/guardians) may decline to continue to take part 
in the trial at any time without prejudice. a decision to 
decline consent or withdraw will not affect the standard 
of care the patient receives. Participants (or their parents/
guardians) can withdraw by contacting the research 
team by telephone or email. upon withdrawal of the pa-
tient, any data collected up until the time of withdrawal 
will be retained by the research team and included in the 
final analysis. Withdrawn patients or patients deemed in-
eligible after randomization will not be replaced.
Blinding. Participants and their parents/guardians can-
not be blind to their treatment. the treating clinician will 
of course, not be blind to the treatment they are provid-
ing. however, the treating clinical team will take no part 
in the follow- up assessment of the patients. the outcome 
data will be collected directly from the participant and/or 
their parents/guardians.
trial treatments
all of the hospitals involved in this trial are familiar with 
both treatment techniques. all of the participants will 
receive analgesia at the discretion of the treating clinician 
as per local guidelines. in the absence of local guidelines, 
clinicians should adhere to the Royal College of emer-
gency medicine best practice guidelines for the manage-
ment of acute pain in children.27
this trial will compare two approaches to treat torus 
fractures of the distal radius in children.
the offer of a soft bandage immobilization and 
immediate discharge. a simple bandage, such as a 
gauze bandage or similar, will be offered to participants. 
the use/discontinuation of the bandage will be at the 
discretion of the child and their parents/guardians. the 
bandage technique involves application to the wrist from 
the middle of the forearm to the level of the metacarpo-
phalangeal joints. Participants will be discharged from 
the emergency department, after randomization, without 
the need for outpatient follow- up (as per niCe guidance). 
it will be advised that the child may return to activities as 
pain allows, a point of contact for any ongoing concern 
will be provided and no specific restrictions are in place. 
it will be advised that the bandage should not be worn 
for more than three weeks. a record will be made of the 
duration that the immobilization is worn.
Rigid splint immobilization. a rigid splint will be 
applied that is either manufactured to conform to the 
wrist (e.g. futura splints), or is moulded onto the wrist 
(i.e. backslab). the study is pragmatic and the exact type 
of splint will not be prescribed to treating clinicians. a 
record will be made of the type of splint used. treatment 
advice and follow- up will be as per the usual practice of 
the treating centre. a record will be made of the duration 
that the immobilization is worn.
Rehabilitation. Physiotherapy does not typically form a 
part in the management of these injuries, and no specific 
guidelines will be offered to clinicians or patients.
Adverse event management
Serious adverse events (Sae) will be entered onto the 
Sae reporting form and reported to the central study 
team. Once notified, causality and expectedness will be 
confirmed by the chief investigator or trial nominated 
clinician. Some adverse events which are foreseeable 
as part of the proposed treatment will not be reported 
on an Sae reporting form; they will be recorded on a 
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complications reporting form. these events include: 
recall to hospital outpatient/emergency department with 
a diagnosis of an alternative fracture pattern, or a wors-
ening fracture deformity (with or without the need for 
differing inpatient or outpatient treatment).
all participants experiencing Saes will be followed up 
as per protocol until the end of the trial. all unexpected 
Saes or SuSaRs that occur between date of consent and 
six weeks follow- up point will be reported to the sponsor 
and ethics committee.
the end of the trial will be defined as the collection/
receipt of the last follow- up questionnaire from the last 
participant.
Analysis
Statistical analysis. a separate statistical analysis plan 
(SaP) with full details of all statistical analyses planned for 
the data has been published alongside this protocol. the 
SaP has been reviewed and received input from the trial 
Steering Committee (tSC) and Data Safety monitoring 
Committee (DSmC).28
any changes or deviations from the original SaP will 
be described and justified in the updated SaP, protocol, 
final report and/or publications, as appropriate. it is 
anticipated that all statistical analysis will be undertaken 
using Stata (StataCorp, College Station, texas, uSa) or 
other well- validated statistical packages.
in equivalence trials a maximum clinical difference 
(Δt) is pre- specified at a level within which the two treat-
ments can be considered not to differ in any clinically 
meaningful way. therefore, the null hypothesis is that 
a difference greater than Δt exists in either direction, 
h0: Δ≤ -Δt or Δ≥ Δt and the trial is targeted to disprove 
this in favour of the alternative that no clinical difference 
exists, ha: - Δt < Δ < Δt.
all analyses will be carried out on the intention- to- 
treat population (that is all patients will be analyzed in 
the group they were randomized to regardless of actual 
treatment received). analyses will be repeated for the per 
protocol population (patients excluded from the per- 
protocol population will be pre- specified in the SaP) and 
only if the results from both the intention- to- treat and per 
protocol analyses show equivalence will equivalence be 
claimed.29,30
the results of the analysis of the primary outcome 
should be one of the following:
8. the confidence interval for the difference of the two 
treatments lies entirely within the equivalence range, -Δt 
to Δt, so that equivalence may be concluded with only a 
small probability of error.
as well as assessing both intention- to- treat and per 
protocol analyses, if equivalence is demonstrated this 
will also form part of an additional sensitivity analysis 
to assess the range of potential biases that could have 
resulted from loss to follow- up, protocol deviations, and 
withdrawal.
Standard descriptive statistics will be used to describe 
the demographics between the treatment groups, 
reporting means and standard deviations or medians and 
interquartile ranges as appropriate for continuous vari-
ables, and numbers and percentages for binary and cate-
gorical variables. Summaries will be presented overall 
and separately for the two age groups. all comparative 
outcomes will be presented as summary statistics and 
reported together with 95% confidence intervals. all tests 
will be carried out at a 5% two- sided significance level.
the Wong- Baker scale at three days post- 
randomization is the primary outcome of the study 
and will be compared between treatment groups as 
the dependent variable in a multivariate linear regres-
sion model, including all patients, and adjusting for 
the stratification factors and participant sex. an unad-
justed t- test will also be undertaken. Separate analyses 
of patients in the two subpopulations (< eight years and 
≥ eight years) will be undertaken using the same meth-
odology. additional analyses utilizing all the time- points 
using multi- level modelling will also be undertaken for 
completeness. these analyses will be performed for the 
available case dataset, if there is a substantial amount of 
missing primary outcome data (> 10%) then sensitivity 
analyses investigating missing not at random scenarios 
will be performed. multi- level linear regression models 
will also be used to analyze continuous secondary 
outcomes and logistic regression models will be used to 
analyze binary secondary outcomes.
Economic evaluation. an economic evaluation will be con-
ducted as part of the trial to estimate cost- effectiveness. 
a health economics analysis Plan (heaP), providing full 
details of the prospective economic analysis, has been 
published alongside this protocol.28 the average staff 
time and time to deliver the rigid immobilization and soft 
bandage treatment will be recorded at each centre, as 
well as materials, and consumables involved. Data will 
be collected on the health service resources used in the 
treatment of each participant during the period between 
randomization and 6 weeks post- randomisation. at three 
and six weeks post- randomization, parents/guardians 
will be asked to complete economic questionnaires pro-
filing their child’s hospital (inpatient and outpatient) and 
community health resource use and as well as their own 
out- of- pocket expenditures and costs associated with 
their lost productivity. unit cost data will be obtained 
from national databases such as the Bnf and PSSRu costs 
of health and social care.31
health- related quality of life will be estimated using 
the euroQol eQ- 5D- y.22,23 Responses to the eQ- 5D- y will 
be converted into health preference scores using estab-
lished methods.32,33 eQ- 5D- y responses will be valued 
using the most appropriate valuation set available for 
the trial population at the time of analysis. if necessary 
the adult eQ- 5D- 3l will be applied, in which case we will 
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undertake sensitivity analysis to make sure that trial find-
ings are not sensitive to the valuation set chosen.
missing data will be explored and managed using 
similar methods to the main statistical analysis. a within- 
trial evaluation will be conducted from a uK nhS and 
Personal Social Services perspective using the fORCe 
trial data.34 an incremental cost- effectiveness analysis, 
expressed in terms of incremental cost per quality- 
adjusted life year (Qaly) gained will be performed using 
bivariate regression. a further regression analysis with an 
interaction term will be fitted in the model to account 
for age as a stratification variable. this approach to age- 
groups differs from the primary outcome analysis because 
cost- effectiveness analysis is concerned with estimation 
rather than equivalence hypothesis testing. Results will 
be presented using incremental cost- effectiveness ratios 
(iCeRs), net benefit and value of information. further-
more, sensitivity analyses will consider the broader issue 
of the generalisability of the study results, including a 
broader societal perspective to include out- off pocket 
expenses borne by participants’ parents/guardians, 
informal care provided by family and friends, and parents/
guardians income loss.
trial oversight
the trial will be carried out in accordance with medical 
Research Council (mRC) good clinical practice and 
applicable uK legislation using the most recently ReC 
approved trial protocol.35 GCP- trained personnel will 
conduct the trial.
the day- to- day management of the trial will be the 
responsibility of the clinical trial manager, based at 
nuffield Department of Orthopaedics, Rheumatology 
and musculoskeletal Sciences and supported by the 
OCtRustaff. this will be overseen by the trial manage-
ment group, who will meet monthly to assess progress.
a tSC and a DSmC will be set up. the DSmC will adopt 
a DamOCleS charter which defines its terms of reference 
and operation in relation to oversight of the trial. they 
will not be asked to perform any formal interim analyses 
of effectiveness. they will, however, see copies of data 
accrued to date, or summaries of that data by treat-
ment group and they will assess the screening algorithm 
against the eligibility criteria. they will also consider 
emerging evidence from other related trials or research 
and review related Saes that have been reported.
Quality control
the study may be monitored, or audited in accordance 
with the current approved protocol, relevant regulations 
and standard operating procedures by the host organi-
zation, Sponsor or appropriate Regulatory authorities. a 
monitoring Plan will be developed according to OCtRu 
standard operating procedures which involves a risk 
assessment. the monitoring activities are based on the 
outcome of the risk assessment and may involve central 
monitoring and site monitoring.
Patient and public involvement
Patients and children were involved from the inception 
of the trial, including in the development of the funding 
application. the study was discussed in detail with 
members of the nihR young Person’s advisory Group 
(nihR yPaG) who chose the logo for study from an online 
design competition. an ongoing commitment has been 
made to continue to work with this group in the produc-
tion of patient- facing materials and the study dissemina-
tion plan.
to ensure ongoing patient and public involvement, a 
patient/carer representative will be actively involved in 
general trial management. in addition, a further indepen-
dent patient/carer representative will become a member 
of the steering committee.
Ethics and dissemination
national Research ethic Committee approved this study 
on the 16 november 2018 with reference number 18/
Wm/0324. the study monograph for the national insti-
tute for health Research health technology assessment 
will be prepared by the trial management team upon 
completion of the trial. a manuscript for a high impact 
peer- reviewed journal will be prepared simultaneously, 
which will allow for the results to be disseminated across 
the orthopaedic and emergency medicine communities, 
the wider medical community, niCe and policy makers. 
authorship will be determined in accordance with the 
iCmJe guidelines and other contributors will be acknowl-
edged. the results of this trial will substantially inform 
clinical practice on the clinical and cost effectiveness of 
the treatment of this injury. the results of this project will 
be disseminated to patients via patient- specific newslet-
ters and through local mechanisms at all participating 
centres. Dissemination is anticipated in Winter 2020.
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